Concepts (65)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms, Castration-Resistant | 3 | 2023 | 111 | 1.130 |
Why?
|
| Androgen Antagonists | 1 | 2023 | 144 | 0.840 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2020 | 1197 | 0.380 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 2 | 2020 | 6 | 0.360 |
Why?
|
| Lutetium | 1 | 2023 | 2 | 0.230 |
Why?
|
| BRCA2 Protein | 2 | 2020 | 158 | 0.220 |
Why?
|
| Androgens | 1 | 2023 | 167 | 0.220 |
Why?
|
| Synthetic Lethal Mutations | 1 | 2020 | 1 | 0.200 |
Why?
|
| src-Family Kinases | 1 | 2020 | 75 | 0.190 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2020 | 14 | 0.190 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 72 | 0.190 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2019 | 70 | 0.170 |
Why?
|
| Prostatic Neoplasms | 2 | 2020 | 1721 | 0.160 |
Why?
|
| Biomarkers, Tumor | 3 | 2020 | 1464 | 0.150 |
Why?
|
| DNA Repair | 1 | 2019 | 356 | 0.150 |
Why?
|
| Cell Proliferation | 2 | 2020 | 1579 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 930 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 592 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 185 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 1313 | 0.120 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 2360 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 1077 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 1 | 2018 | 1052 | 0.100 |
Why?
|
| Male | 6 | 2023 | 40988 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 458 | 0.080 |
Why?
|
| Prognosis | 3 | 2020 | 3680 | 0.080 |
Why?
|
| Survival Rate | 2 | 2020 | 1864 | 0.070 |
Why?
|
| Humans | 7 | 2023 | 86678 | 0.070 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 2426 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2020 | 2768 | 0.060 |
Why?
|
| Cryoglobulins | 1 | 2020 | 4 | 0.050 |
Why?
|
| Gene Ontology | 1 | 2020 | 34 | 0.050 |
Why?
|
| Phenylthiohydantoin | 1 | 2020 | 41 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2020 | 303 | 0.050 |
Why?
|
| Rituximab | 1 | 2020 | 116 | 0.050 |
Why?
|
| Nitriles | 1 | 2020 | 149 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2020 | 172 | 0.040 |
Why?
|
| Forkhead Box Protein M1 | 1 | 2019 | 13 | 0.040 |
Why?
|
| Benzamides | 1 | 2020 | 229 | 0.040 |
Why?
|
| RNA Interference | 1 | 2020 | 369 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 1041 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2020 | 260 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2020 | 790 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 187 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 357 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 134 | 0.040 |
Why?
|
| Genes, BRCA2 | 1 | 2019 | 160 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2019 | 252 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 895 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2019 | 280 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2020 | 715 | 0.040 |
Why?
|
| Computational Biology | 1 | 2020 | 528 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 418 | 0.040 |
Why?
|
| Mice | 2 | 2020 | 11356 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 1939 | 0.030 |
Why?
|
| Transcriptome | 1 | 2019 | 580 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 1384 | 0.030 |
Why?
|
| Apoptosis | 1 | 2020 | 1683 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2019 | 2819 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2018 | 629 | 0.030 |
Why?
|
| Phenotype | 1 | 2019 | 2380 | 0.030 |
Why?
|
| Middle Aged | 2 | 2020 | 25040 | 0.020 |
Why?
|
| Animals | 2 | 2020 | 26590 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 2438 | 0.020 |
Why?
|
| Female | 1 | 2020 | 44550 | 0.010 |
Why?
|